Cost-effectiveness of pneumococcal polysaccharide vaccine among healthcare workers during an influenza pandemic

American Journal of Managed Care

Volumn 16, Issue 3, 2010, Pages 200-206

  Smith, Kenneth J ^a   Raymund, Mahlon ^b   Nowalk, Mary Patricia ^b   Roberts, Mark S ^a   Zimmerman, Richard K ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; HEALTH CARE COST; HEALTH CARE PERSONNEL; HUMAN; INCIDENCE; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; PANDEMIC; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

COST-BENEFIT ANALYSIS; DISEASE OUTBREAKS; FEMALE; HEALTH PERSONNEL; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; INFLUENZA, HUMAN; MALE; MARKOV CHAINS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; QUALITY-ADJUSTED LIFE YEARS;

EID: 77950613368     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. National Center for Immunization and Respiratory Diseases, CDC; Centers for Disease Control and Prevention (CDC). Use of influenza A (H1N1) 2009 (monovalent) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep. 2009;58(RR-10):1-8.
2. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis. 2008;198(7):962-970.
3. Brundage JF. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis. 2006;6(5):303-312.
4. O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis. 2007;7(9):597-606.
5. Arias E. United States life tables, 2002. Natl Vital Stat Rep. 2004;53(6):1-38.
6. Musher DM. Streptococcus pneumoniae. In: Mandell GL, Douglas RG, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. New York, NY: Elsevier/Churchill Livingstone; 2005.
7. Gold M, Siegel J, Russell L, Weinstein M. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
8. Centers for Disease Control and Prevention. Active Bacterial Core surveillance report. Emerging Infections Program Network, Streptococcus pneumoniae, 2007. Updated December 1, 2008. http://www.cdc.gov/abcs/reports- findings/survreports/spneu07.pdf. Accessed March 3, 2010.
9. US Department of Health and Human Services. The registered Registered Nurses. Updated 2004. http://bhpr.hrsa.gov/healthworkforce/rnsurvey04/3.htm. Accessed October 1, 2009.
10. US Department of Health and Human Services. National Center for Health Workforce Analysis: supply, demand, and use of licensed practical nurses. Updated November 1, 2004. http://bhpr.hrsa.gov/healthworkforce/reports/lpn/LPN1- 5.htm. Accessed October 1, 2009.
11. Centers for Disease Control and Prevention (CDC). Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1): United States, May-August 2009. MMWR Morb Mortal Wkly Rep. 2009;58(38):1071- 1074.
12. Smith KJ, Zimmerman RK, Lin CJ, et al. Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis. Vaccine. 2008;26(11):1420-1431.
13. Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med. 2003;138(12):960-968. (Pubitemid 38129116)
14. Centers for Disease Control and Prevention. CDC vaccine price list. 2009. http://www.cdc.gov/vaccines/programs/vfc/cdc-vac-price-list.htm. Accessed July 8, 2009.
15. Centers for Medicare and Medicaid Services. Physician Fee Schedule look-up. 2007. http://www.cms.hhs.gov/PFSlookup/. Accessed August 29, 2009.
16. Centers for Medicare and Medicaid Services. Payment allowances for the influenza virus vaccine (CPT 90655, 90656, 90657, and 90658) and the pneumococcal vaccine (CPT 90732) when payment is based on 95 percent of the average wholesale price (AWP). 2007. http://www.cms.hhs.gov/MLNMattersArticles/ downloads/MM4109.pdf. Accessed August 27, 2009.
17. Messonnier ML, Zhou F, Moore MR. Cost-effectiveness of using 23-valent pneumococcal polysaccharide vaccine to prevent pneumococcal pneumonia in target population groups during an influenza pandemic in the United States. Updated 2009. http://www.cdc.gov/vaccines/recs/acip/downloads/mtg-slides-feb09/07-2- pneu.pdf. Accessed August 11, 2009.
18. Jackson LA, Benson P, Sneller VP, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA. 1999;281(3):243-248. (Pubitemid 29058113)
19. US Bureau of Labor Statistics. Average hourly earnings of production workers, general medical and surgical hospitals, 2006. Updated 2008. Accessed August 7, 2009.
20. Kamal-Bahl SJ, Pantely S, Pyenson B, Alexander CM. Employer-paid nonmedical costs for patients with diabetes and end-stage renal disease. Prev Chronic Dis. 2006;3(3):eA83. http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC1636708/?tool=pubmed. Accessed February 13, 2010.
21. Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998;36(6):778-792.
22. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991;325(21):1453-1460.
23. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008;46(4):349-356.
24. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? tentative guidelines for using clinical and economic evaluations. CMAJ. 1992;146(4):473-481.
25. Hirth RA, Chemew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20(3):332-342. (Pubitemid 30479101)
26. Moore MR; Advisory Committee on Immunization Practices. Use of 23-valent pneumococcal polysaccharide vaccine for prevention of pneumococcal pneumonia during an influenza pandemic: potential role among critical infrastructure personnel. http://www.cdc.gov/vaccines/recs/ACIP/downloads/mtg-slides-feb09/07- 1-pneu.pdf. Updated February 22, 2009. Accessed August 11, 2009.
27. Conaty S, Watson L, Dinnes J, Waugh N. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine. 2004;22(23-24):3214-3224. (Pubitemid 39037227)
28. Cornu C, Yzèbe D, Léophonte P, Gaillat J, Boissel JP, Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine. 2001;19(32):4780-4790. (Pubitemid 32800764)
29. Dear K, Holden J, Andrews R. Tatham D. Vaccines for preventing pneumococcal infection in adults [update in Cochrane Data-base Syst Rev. 2008;(1):CD000422]. Cochrane Database Syst Rev. 2003;(4):CD000422.
30. Jackson LA, Neuzil KM. Pneumococcal polysaccharide vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. Philadelphia, PA: Saunders Elsevier Inc; 2008:569-604.
31. Yekutiel P. Lessons from the big eradication campaigns. World Health Forum. 1981;2:465-490.
32. Centers for Disease Control and Prevention. ACIP provisional recommendations for use of pneumococcal vaccines. Updated October 22, 2008. http://www.cdc.gov/vaccines/recs/provisional/downloads/pneumo-Oct-2008-508.pdf. Accessed August 29, 2009. ■